SILO

Silo Pharma Inc. (SILO) | Rumor.io

Silo Pharma

SILO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,999

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.22

Market capitalization2.9M

Earnings per share-3.74

Dividend yield (TTM)—

Revenue (annual)72.1K

Net income (annual)-4.2M

Social

What share of all stock conversation is about SILO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 7

The author is optimistic about Silo Pharma, Inc. (SILO) and expects it to increase in value, potentially reaching $18.
The company's low volume is seen as a positive factor, and the author believes it will lead to a significant price increase.
Silo Pharma's tests are priced at $32, $42, $52.66, and $66.82, and the author believes the stock has accumulation and a strong upside potential.

Generated by AI

Sentiment

Of the messages about SILO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	84.89% -3.51
Bearish	—	0%	0% 0	15.11% +3.51

Bullish· Jul 7

The author believes $SILO has a high chance of a significant price increase due to low volume and accumulation.
The asset has a low float of 1.04M shares, which could contribute to its potential for a price explosion.
The author is optimistic about $SILO's AI subsidiary, QwikAgents, joining the NVIDIA Developer Program, which could lead to another price push.

Bearish· Apr 20

$SILO is predicted to drop to $1 by Friday, with the worst expected on days 4 and 5.
The stock's performance is compared unfavorably to another, with the suggestion to buy the latter ($PBM) instead.
The stock is described as "trash" and its price is seen as likely to continue falling.

Generated by AI

Topics

Of the messages about SILO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50%	74.39%
Controversies	50%	50%	50%	0.91%
Analysts	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	24.7%

Announcements· Apr 28

Silo Pharma Inc. (NASDAQ: SILO) has filed a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel Alzheimer's treatment.
The patent application covers SPC-14's mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer's disease.
Silo Pharma has exclusively licensed SPC-14 from Columbia University and has filed a patent application with the U.S. Patent and Trademark Office to expand its intellectual property portfolio.

Technical Analysis· Jan 8

$SILO has a short pattern forming above a key daily level, creating a potential short opportunity for day traders and short sellers.
The stock is in a 3-pump structure, which could close the gap and potentially lead to a pullback for dip players.
The RSI has just passed 70, indicating a potential round of buying activity, and the stock is also forming a bullish triangle.

Generated by AI

Community

Of the messages about SILO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92.31%	92.31%	28.28%
Newcomers	0%	7.69%	7.69%	71.72%

Regulars· Jan 8

$SILO has been awarded a US patent for a groundbreaking PTSD treatment, and preparations are underway for the SPC-15 clinical trial.
The company's stock is showing resilience, with a recent surge in price and a low float of around 5 million shares, contributing to a 57% pre-market price.
The stock's performance has been impressive, with a four-perfect scalp entries resulting in a significant green day, leaving participants optimistic about the company's prospects.

Newcomers· Jun 5

The company has secured a patent for a nasal spray to treat PTSD, with SPC-15 ready to roll.
The SP-26 implant has shown positive safety results for treating chronic pain and fibromyalgia.
The company has raised $2 million, giving it a war chest for upcoming trials.

Generated by AI

News

Silo Pharma receives U.S. patent allowance for PTSD treatment

11d agoInvesting.com

Silo Pharma Acquires Digital Assets via Stock Issuance

Detailed price information for Silo Pharma Inc (SILO-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Silo Pharma receives Canadian patent allowance for SPC-15 drug

1mo agoInvesting.com

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

1mo agoBarchart.com

Silo Pharma receives European patent for SPC-15 PTSD treatment

1mo agoInvesting.com

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop

1mo agoBarchart.com

Also Discussed

Investors talking about SILO also mention

#	Name	Attention
1	Clearmind Medicine Inc. Common SharesCMND	0%new
2	Lucyd, Inc.LUCY	0%0
3	BNOX - Bionomics Limited	——
4	Dermata Therapeutics, Inc.DRMA	0%new
5	SMFL - Smart for Life, Inc.	——
6	Mira Pharmaceuticals, Inc.MIRA	0%0
7	ZAPP - Zapp Electric Vehicles Group Limited	——
8	ARCK - Arbor Rapha Capital Bioholdings Corp. I	——
9	ASNS - Actelis Networks, Inc.	——
10	PMNT - Perfect Moment Ltd. Common Stock	——

Silo Pharma Inc.

Healthcare
Biotechnology

Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases such as Alzheimer's and multiple sclerosis. The company merges traditional therapies with psychedelic medicine, utilizing innovative formulations and drug delivery systems like intranasal treatments and time-release implants. Its lead program, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety. SP-26 is a ketamine-based injectable dissolvable implant designed for fibromyalgia and chronic pain relief. Preclinical efforts include SPC-14, an intranasal compound for Alzheimer's disease, and SPU-16, a CNS-homing peptide for multiple sclerosis. Silo Pharma acquires intellectual property from universities and researchers, pursuing streamlined clinical pathways. Founded in 2010 and headquartered in Sarasota, Florida, the company partners with leading academic institutions to advance its pipeline of psychedelic and conventional treatments for psychiatric and neurological disorders.

Website

Location

677 North Washington Boulevard

Sarasota, FL, 34236

United States

Social

What share of all stock conversation is about SILO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 7

The author is optimistic about Silo Pharma, Inc. (SILO) and expects it to increase in value, potentially reaching $18.
The company's low volume is seen as a positive factor, and the author believes it will lead to a significant price increase.
Silo Pharma's tests are priced at $32, $42, $52.66, and $66.82, and the author believes the stock has accumulation and a strong upside potential.

Generated by AI

Sentiment

Of the messages about SILO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	84.89% -3.51
Bearish	—	0%	0% 0	15.11% +3.51

Bullish· Jul 7

The author believes $SILO has a high chance of a significant price increase due to low volume and accumulation.
The asset has a low float of 1.04M shares, which could contribute to its potential for a price explosion.
The author is optimistic about $SILO's AI subsidiary, QwikAgents, joining the NVIDIA Developer Program, which could lead to another price push.

Bearish· Apr 20

$SILO is predicted to drop to $1 by Friday, with the worst expected on days 4 and 5.
The stock's performance is compared unfavorably to another, with the suggestion to buy the latter ($PBM) instead.
The stock is described as "trash" and its price is seen as likely to continue falling.

Generated by AI

Topics

Of the messages about SILO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50%	74.39%
Controversies	50%	50%	50%	0.91%
Analysts	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	24.7%

Announcements· Apr 28

Silo Pharma Inc. (NASDAQ: SILO) has filed a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel Alzheimer's treatment.
The patent application covers SPC-14's mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer's disease.
Silo Pharma has exclusively licensed SPC-14 from Columbia University and has filed a patent application with the U.S. Patent and Trademark Office to expand its intellectual property portfolio.

Technical Analysis· Jan 8

$SILO has a short pattern forming above a key daily level, creating a potential short opportunity for day traders and short sellers.
The stock is in a 3-pump structure, which could close the gap and potentially lead to a pullback for dip players.
The RSI has just passed 70, indicating a potential round of buying activity, and the stock is also forming a bullish triangle.

Generated by AI

Community

Of the messages about SILO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	92.31%	92.31%	28.28%
Newcomers	0%	7.69%	7.69%	71.72%

Regulars· Jan 8

$SILO has been awarded a US patent for a groundbreaking PTSD treatment, and preparations are underway for the SPC-15 clinical trial.
The company's stock is showing resilience, with a recent surge in price and a low float of around 5 million shares, contributing to a 57% pre-market price.
The stock's performance has been impressive, with a four-perfect scalp entries resulting in a significant green day, leaving participants optimistic about the company's prospects.

Newcomers· Jun 5

The company has secured a patent for a nasal spray to treat PTSD, with SPC-15 ready to roll.
The SP-26 implant has shown positive safety results for treating chronic pain and fibromyalgia.
The company has raised $2 million, giving it a war chest for upcoming trials.

Generated by AI

Silo Pharma

Social

Jul 7

Bullish· Jul 7

Bearish· Apr 20

Announcements· Apr 28

Technical Analysis· Jan 8

Regulars· Jan 8

Newcomers· Jun 5

Silo Pharma receives U.S. patent allowance for PTSD treatment

Silo Pharma Acquires Digital Assets via Stock Issuance

Silo Pharma receives Canadian patent allowance for SPC-15 drug

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Silo Pharma receives European patent for SPC-15 PTSD treatment

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Also Discussed

Silo Pharma Inc.

Company Information

Location

Silo Pharma receives U.S. patent allowance for PTSD treatment

Silo Pharma Acquires Digital Assets via Stock Issuance

Silo Pharma receives Canadian patent allowance for SPC-15 drug

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Silo Pharma receives European patent for SPC-15 PTSD treatment

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Also Discussed

Social

Jul 7

Bullish· Jul 7

Bearish· Apr 20

Announcements· Apr 28

Technical Analysis· Jan 8

Regulars· Jan 8

Newcomers· Jun 5